Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
46 hedge funds and large institutions have $22.8M invested in Enzo Biochem, Inc. in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
18% more funds holding
Funds holding: 39 → 46 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $23.1M → $22.8M (-$312K)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$306K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$196K |
| 3 |
FIA
FNY Investment Advisers
New York
|
+$101K |
| 4 |
Morgan Stanley
New York
|
+$101K |
| 5 |
WIM
Wittenberg Investment Management
Carlisle,
Massachusetts
|
+$90.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$663K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$150K |
| 3 |
Renaissance Technologies
New York
|
-$102K |
| 4 |
SC
Shay Capital
New York
|
-$87.5K |
| 5 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
-$12.2K |
ENZ Hedge Fund Activity: Q4 2023 in Review
46 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2023, worth a combined $22.8M — down 1.3% from $23.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ENZ positions and 3 closed out — a net gain of 7 holders — while 8 added to existing stakes and 9 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $306K. The largest seller was Tang Capital Management, cutting an estimated $663K.
- 46 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2023, up from 39 in Q3 2023.
- Funds reported $22.8M of Enzo Biochem, Inc. stock for Q4 2023, down 1.3% quarter-over-quarter.
- 10 funds opened new Enzo Biochem, Inc. positions in Q4 2023 and 3 closed out, a net change of +7 holders.
- The largest Enzo Biochem, Inc. buyer in Q4 2023 was Anson Funds Management, an estimated $306K added.
- The largest Enzo Biochem, Inc. seller in Q4 2023 was Tang Capital Management, an estimated $663K sold.
Based on aggregated 13F filings for Q4 2023.